Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now

Glaukos is viewed as a Hold despite a 35.9% year-to-date share gain, supported by iDose re-administration potential, Epioxa's $11 million first full commercial quarter, and Q2 gross margin expansion to approximately 85% (+90bps sequentially). Consensus forecasts 2026 revenue of $689.7 million, up 36% year over year, while projected loss per share narrows 64.4% to $0.32. Key risks include potentially moderating iDose growth, Epioxa net pricing pressure from reimbursement and channel mix, international competitive and FX headwinds, and approximately $600 million of expected 2026 operating expenses delaying profitability.

Analysis

GKOS is transitioning from a procedure-driven MIGS company to a higher-lifetime-value implant/pharma model, but the market is likely already capitalizing much of that optionality after the year-to-date rerating. The key modeling variable is not headline adoption but repeat-treatment cadence, account-level utilization, and net revenue retention after payer discounts. If re-administration becomes routine, the installed base creates a deferred annuity-like revenue stream that supports a premium multiple; if it remains confined to early-adopter sites, revenue will look episodic and the valuation premium becomes vulnerable.

Near-term risk is asymmetric into the next two quarterly reports: seasonal procedure softness and a ramping reimbursement mix can produce a revenue beat while disappointing on utilization, net price, or operating-expense discipline. With a high gross margin, incremental revenue should be highly valuable only once commercial spending plateaus; continued investment can postpone the EBITDA inflection and prompt multiple compression despite intact top-line growth. International pricing pressure also makes domestic launches carry a larger share of the growth burden, increasing execution sensitivity.

Contrarian view: the market may be underestimating the strategic value of a reimbursement-enabled treatment-center network, which can become a barrier to entry in corneal cross-linking rather than merely a distribution expense. Conversely, payer coverage is not equivalent to frictionless patient throughput: referral behavior, prior authorization, and site economics determine conversion. The decisive 6-18 month evidence is net revenue per Epioxa treatment, repeat iDose penetration, and sales-force productivity—not additional access announcements.

Key Decisions for Investors

• Maintain GKOS as a watch-to-add rather than chase position over the next 1-3 months. Add only following a post-earnings pullback if iDose account utilization and repeat-treatment disclosure remain intact; target 15-20% upside over 12 months from evidence of durable net-revenue retention, with thesis invalidated by two consecutive quarters of below-guidance iDose growth or a material reduction in gross-margin outlook.
• Use a defined-risk bullish structure for the 6-12 month commercialization window: buy GKOS call spreads rather than outright calls after confirming liquid strikes and implied volatility. The trade requires verification of current option pricing; avoid if the premium paid exceeds roughly one-third of the spread width, since reimbursement and seasonal uncertainty can delay the catalyst.
• Pair a modest long GKOS with short IHI only if GKOS reports accelerating repeat utilization while maintaining operating-expense guidance. This isolates company-specific commercialization execution from broad medtech multiple risk; close if realized Epioxa revenue per treatment declines materially or the pair underperforms by 10% after the next earnings report.
• Prefer GMED or WST for core medtech exposure while waiting for GKOS evidence, given their more established earnings conversion. VCYT is not a clean substitute: its diagnostic reimbursement and volume drivers differ, making it useful only as a separate growth-healthcare allocation rather than a hedge.